Understanding Clinical Research Programs for Life Science Startups

Navigating the clinical research landscape is a crucial, yet complex journey for life science startups. The transition from promising preclinical results to successful clinical trials can be fraught with challenges, as not all well-designed studies yield favorable outcomes in humans. For instance, while the checkpoint inhibitor Keytruda (pembrolizumab) successfully translated its preclinical promise into a multi-billion-dollar success, other ventures, like the c47 checkpoint inhibitor, failed in late-stage trials despite initial high expectations. This dichotomy highlights the unpredictable nature of clinical research programs and the high stakes involved in transforming scientific innovation into therapeutic reality.

Clinical research is a crucial phase for life science startups, as it translates innovative ideas into tangible products and therapies. For startups navigating this complex field, understanding the various options and considerations for conducting clinical trials is essential. This article explores the regional concentration of investments, the role of Contract Research Organizations (CROs), and effective strategies for managing clinical trial operations.

🔬Read more about choosing the correct CRO

What is a Clinical Trial Program?

Clinical trials are essentially experiments designed to test scientific hypotheses in human subjects, with a focus on safety and efficacy. They are governed by strict ethical guidelines and regulations to ensure patient safety. Trials often fail due to incorrect hypotheses, unforeseen safety issues, or experimental errors. Ensuring robust study design is critical, and this involves selecting the right patient populations, determining appropriate endpoints, and choosing the correct methodology for administration and monitoring.

🔬Learn about study protocols here

Designing Clinical Trials

A well-designed clinical trial addresses several key elements:

• Who: Identifies the patient population, including disease stage, inclusion/exclusion criteria, and comorbidities.
• What: Defines the intervention being tested, such as a new drug or device, and its comparison to current standards of care or placebo.
• How: Involves determining sample size, statistical power, and trial design, such as randomized controlled trials versus open-label studies.

For instance, if a startup develops an AI-driven tool for academic research, it might test its efficacy by comparing the number of publications produced by users of the tool against a control group using traditional methods. Key endpoints could include publication quantity and user stress levels.

🔬Read more about the influence of AI on startups

Cost Considerations

Clinical trials are notoriously expensive. Data from studies on pharmaceutical trials suggest median costs of approximately $3.4 million for Phase 1, $8.6 million for Phase 2, and $21.4 million for Phase 3. These costs are subject to inflation and variability based on patient numbers and disease types. Rare diseases with limited patient populations may result in lower costs due to smaller trial sizes, while more common conditions with larger patient groups may drive up costs.

🔬Learn more about strategies for funding research

Funding and Market Trends

Funding for clinical trials primarily comes from venture capital and public markets. Venture capital remains a significant source, but the volume of deals has decreased, making it more competitive. Public market interest has shifted towards clinical-stage companies, reflecting a preference for lower-risk investments with demonstrated efficacy.

Recent trends show a decline in preclinical funding, with more investments focusing on companies that have reached clinical stages. This shift indicates a strategic move towards de-risked opportunities, aligning with the overall market environment that favors proven advancements over early-stage speculation.

In summary, life science startups must navigate a complex clinical research landscape, balancing the high costs and risks associated with developing new drugs and devices. Successful clinical trials involve meticulous planning and robust study design, addressing patient populations, intervention comparisons, and appropriate methodologies. As funding dynamics shift towards clinical-stage investments, startups must strategically focus on advancing their most promising programs to achieve significant value inflection points and secure necessary funding.

🔬Learn more about top Venture Capital firms

Pharmaceutical vs. Medical Device Clinical Research Trials 

Ultimately, clinical research programs can be divided into two main categories: trials focusing on pharmaceutical products and trials focusing on the development of medical devices. 

Pharmaceuticals

Pharmaceutical clinical trials are categorized into several phases:

1. Phase 1: This initial phase tests the safety and dosage of a new drug, typically involving 20 to 100 participants. It lasts for several weeks and focuses on identifying any serious side effects and determining safe dosage levels.
2. Phase 2: Expanding to 35 to 300 participants, this phase begins to evaluate the drug’s efficacy and further examines its safety. It provides initial insights into whether the drug produces the intended effects.
3. Phase 3: This crucial phase involves 100 to 3,000 participants and compares the new drug against a placebo or current standard of care. It provides comprehensive data on effectiveness and safety, leading to regulatory approval if successful.
4. Phase 4: Post-marketing surveillance monitors long-term effects and effectiveness in a larger population. This phase helps identify rare side effects and ensures ongoing safety.

For example, CAR T-cell therapies, approved for certain cancers, have shown efficacy but also revealed potential long-term risks, highlighting the importance of ongoing post-market surveillance.

🔬Read about tips for partnering with Big Pharma

Medical Devices

Medical device trials differ from pharmaceuticals and are generally categorized into:

1. Pilot Studies: These exploratory studies test the device on a small scale to gather preliminary data on its functionality and safety.
2. Pivotal Studies: This phase involves larger, more rigorous testing to meet regulatory requirements for approval. It is akin to Phase 3 in pharmaceuticals and focuses on confirming efficacy and safety in a broader population.
3. Post-Market Surveillance: After approval, ongoing monitoring ensures the device performs as expected in real-world settings and identifies any unforeseen issues.

🔬Read more about Medical Device product development here

Regional Concentration of Capital for Biomedical Investments

Biomedical investments are notably concentrated in specific regions known for their robust life science ecosystems. Historically, Boston, Massachusetts and the Bay Area in California have been pivotal hubs for biotech investments. These regions benefit from a dense network of incubators, venture capitalists, and established biotech companies that drive innovation and funding. San Diego also holds significant promise as a third major hub, though it still lags behind Boston and the Bay Area in terms of deal volume and investment size.

🔬Read more about networking for Biotech startups 

The influx of capital into biotech has fluctuated, with a notable spike during the COVID-19 pandemic. The low-interest-rate environment and heightened public interest in healthcare led to increased investments in vaccine development and immunotherapies. This surge, however, has since tapered off, revealing a more cautious investor landscape.

🔬Learn more about business resources for Biotech startups 

The Contract Research Organization Ecosystem

Life science startups often face the decision of whether to build an internal clinical operations team or outsource these functions to Contract Research Organizations (CROs). CROs offer a range of services that can be particularly beneficial for smaller companies with limited resources. They handle various aspects of clinical research programs, from site management to patient recruitment, which allows startups to focus on their core innovations.

CROs, such as Namer, PD, and IIA, provide essential support by managing clinical trial operations and liaising with trial sites. This can be advantageous for startups that lack the infrastructure to handle these processes in-house. On the other hand, large pharmaceutical companies might build internal teams to maintain tighter control over their trials and potentially expedite the process.

🔬Learn more about effective CRO collaboration

Clinical Trial Operations Overview

Effective management of clinical trials involves several key steps, whether conducted internally or through a CRO. Initially, a startup must engage with potential trial sites and establish a Clinical Trial Agreement (CTA) to protect both parties. Feasibility assessments are conducted to ensure that sites have the necessary resources and patient populations.

Pre-site selection visits are crucial for evaluating trial sites and understanding their capabilities. Once a site is selected, the trial activation process begins, requiring detailed documentation, including the clinical protocol, budget, and informed consent forms. Efficient management throughout the trial is vital to ensure adherence to timelines and data integrity.

🔬Learn about guidelines for clinical engagement for healthcare startups

CRO Considerations

When selecting a CRO, startups should evaluate several factors:

• Service Offerings: Ensure the CRO provides comprehensive services, including pharmacokinetics (PK), pharmacodynamics (PD), medical writing, biostatistics, and patient recruitment.
• Experience and Expertise: Look for CROs with experience in your specific therapeutic area and a track record of managing similar trials.
• Geographic Coverage: Geographic diversity is increasingly important due to FDA guidelines on trial diversity.
• Cost and Relationship: Understand the cost structure and maintain a transparent relationship with the CRO to ensure effective communication and project management.
• Technology: Assess the usability of the CRO’s technology platforms for data management and reporting.

Introducing the Center for Clinical Research at UCI

The Center for Clinical Research at UC Irvine exemplifies a dedicated institution supporting clinical trials in non-oncology and non-stem cell areas. Established around 2018-2019, the center consolidates resources from various departments to enhance efficiency and streamline clinical operations.

The center aims to become a leading clinical research organization, offering world-class solutions and accelerating the delivery of novel therapies. Its team includes experienced medical directors, clinical research staff, and a dedicated nursing team. The center's infrastructure includes advanced facilities and electronic systems to ensure high-quality data management and compliance with ethical standards.

The typical timeline from initial contact to trial activation at the center is approximately four months, covering steps such as feasibility assessment, budget negotiation, and regulatory approvals. The center supports startups through every stage of the clinical trial process, from patient recruitment to data management and final analysis.

For life science startups, choosing the right clinical research strategy is crucial for translating innovative ideas into successful products. By leveraging regional investment hubs, partnering with experienced CROs, and understanding the detailed processes of clinical trial operations, startups can navigate the complexities of clinical research effectively. Institutions like UC Irvine's Center for Clinical Research offer valuable resources and expertise to support this journey, ensuring that promising therapies reach the market efficiently and ethically.

🔬Read more about UCI’s Center for Clinical Research!